Breast Cancer Research and Treatment **62:** 259–260, 2000.
© 2000 *Kluwer Academic Publishers. Printed in the Netherlands.*

Authors Index, Volume 62

Aiba M 177
Ajarim DS 237
Al-Malik OA 237
Audisio RA 217
Andersen JA 197

Balducci L 141
Bazarbashi SM 237
Beek MWPM van 63
Berghammer P 253
Blichert-Toft M 197
Bonito M Di 87
Boss GR 51
Broeckel JA 141
Brown PH 1

Capasso I 87
Carrasco J 127
Carteni G 87
Casteel DE 51
Castiglione F 217
Chavez JB 109
Christensen IJ 197
Coebergh J-WW 63
Comandini D 217
Comella G 87
Comella P 87
Conneely OM 185
Crommelin MA 63

D'Aiuto G 87
D'Aniello R 87
Demicheli R 135
Diamandis EP 35
Disis ML 245
Dreilinger AD 51
Driel OJ R van 63
Du X 71
Duigou F 117

Eischeid A 167
Esteban E 127
Ezzat AA 237

Fernberg J-O 211
Fernández JL 127
Fokstuen T 211
Fra J 127
Frasci G 87
Freeman DH Jr 71
Frezza P 87

Garbagnati F 135
Gewirtz DA 223
Goodwin PJ 19
Goss PE 151
Granetto C 217
Graversen HP 197

Haga S 177
Horton J 141

Ibrahim EM 237
Imamura H 177

Jacobsen PB 141
Jeng M-H 167
Jenkins DJA 35
Jiang Y 99
Jin T 151

Kajiwara T 177
Kandil A 237
Kinoshita J 177
Knutson KL 245
Kubista E 253

Lacave AJ 127
Lapenta L 87
Li H 151
Liedberg A 211
Lippman SM 1
Liu J 99
Liu YE 99
Lucia L De 87
Lyman GH 141

Maiorino L 87
Mariani G 135
Marnay J 117
McNeel DG 245
Medina D 185
Michels J-J 117
Modollel A 127
Muellauer-Ertl S 253
Muñiz I 127

Nagumo H 177
Nawaz Z 185

O'Malley BW 185
Obwegeser R 253
Ottesen GL 197

Palacio I 127
Patil R 109
Potepan P 135
Puertas J 127

Rahal MM 237
Raja MA 237
Repetto L 217
Rinn K 245
Rivellini F 87
Rosso R 217
Roumen RMH 63
Rutqvist LE 211

Sala M 127
Sande G de 127
Santen RJ 167
Schiffman K 245
Shi YE 99
Shimizu T 177
Signomklao T 211
Sinzinger H 253
Sivaraman L 185
Spence MJ 99
Stuart RK 237

Syblik DA 71

Thomas R 87
Tulbah AM 237

Varki NM 51
Venturino A 217
Verderio P 135
Vieitez JM 127
von Lintig FC 51
Voogd AC 63
Vreugdenhil A 63

Wallace AM 51
Wang J-P 167
Watanabe O 177
Wilking N 211
Wolke J 211

Yee D 109
Yue W 167

Zambetti M 135
Zand RRS 35
Zhang X 151
Zhang YL 99

Breast Cancer Research and Treatment **61:** 261–263, 2000.
© 2000 *Kluwer Academic Publishers. Printed in the Netherlands.*

Subject index, Volume 62

99m-Tc-tetrofosmin
  tetrofsomin in breast cancer diagnosis 253-258
adjuvant chemotherapy
  quality of life after adjuvant chemotherapy for breast cancer 141-150
adriamycin
  growth arrest and cell death in the breast tumor cell 223-235
advanced breast cancer
  cyclophosphamide, epirubicin and vinorelbine in 127-133
age
  and intraductal components in breast cancer 177-184
antibody
  immunity to HER-2/neu in advanced cancer 245-252
apoptosis
  growth arrest and cell death in the breast tumor cell 223-235
aromatase
  a novel silencer element in the aromatase PII promoter 151-159
axillary dissection
  modal metastases in breast cancer patients with clinically negative lymph nodes 63-69
brain metastases
  radiation therapy in the management of brain metastases from breast cancer 211-216

BRCA1
  management of familial breast cancer risk 19-33
BRCA2
  management of familial breast cancer risk 19-33
breast cancer cell growth
  transcriptional suppression of synuclein γ by oncostatin M 99-107
breast carcinoma
  flow cytometry in primary breast carcinomas 117-126
breast conserving surgery
  changes in the use of 71-79
  carcinoma *in situ* of the female breast 197-210
bystander effect
  inducible expression of HSV-tK in breast cancer cells 109-115

cancer prevention
  steroid hormonal activity of flavonoids and related compounds 35-49
cancer risk
  steroid hormonal activity of flavonoids and related compounds 35-49
carcinoma *in situ*
  carcinoma *in situ* of the female breast 197-210
celebrity
  changes in the use of breast conserving surgery 71-79
cell proliferation
  MAPK in breast cancer re-growth 167-175
chemotherapy
  paclitaxel and cisplatin for locally advanced breast cancer 237-244
cisplatin
  cisplatin-epirubicin-paclitaxel in advanced breast cancer 87-97
  paclitaxel and cisplatin for locally advanced breast cancer 237-244
clinical trial
  changes in the use of breast conserving surgery 71-79
combination chemotherapy
  cyclophosphamide, epirubicin and vinorelbine in advanced breast cancer 127-133
comorbidity
  formestane in elderly breast cancer patients 217-222
consensus statement
  changes in the use of breast conserving surgery 71-79
cyclophosphamide
  cyclophosphamide, epirubicin and vinorelbine in advanced breast cancer 127-133

diet and cancer
  steroid hormonal activity of flavonoids and related compounds 35-49
disability

formestane in elderly breast cancer patients 217-222
DNA damage
growth arrest and cell death in the breast tumor cell 223-235

E6-AP
E6-AP and mouse mammary tumorigenesis 185-195
elderly
formestane in elderly breast cancer patients 217-222
EMSA
a novel silencer element in the aromatase PII promoter 151-159
epidermal growth factor receptor
ras activation in human breast cancer 51-62
epirubicin
cisplatin-epirubicin-paclitaxel in advanced breast cancer 87-97
cyclophosphamide, epirubicin and vinorelbine in advanced breast cancer 127-133
ErbB-2 receptor
ras activation in human breast cancer 51-62
estrogen deprivation
MAPK in breast cancer re-growth 167-175
estrogen receptor
deprivation MAPK in breast cancer re-growth 167-175
estrogen-like compounds
steroid hormonal activity of flavonoids and related compounds 35-49
estrogens
a novel silencer element in the aromatase PII promoter 151-159

familial risk
management of familial breast cancer risk 19-33
flavonoids
steroid hormonal activity of flavonoids and related compounds 35-49
flow cytometry
flow cytometry in primary breast carcinomas 117-126
formestane
in elderly breast cancer patients 217-222

ganciclovir
inducible expression of HSV-tK in breast cancer cells 109-115
GATA
a novel silencer element in the aromatase PII promoter 151-159
gene therapy
inducible expression of HSV-tK in breast cancer cells 109-115
gene transcription
transcriptional suppression of synuclein γ by oncostatin M 99-107
growth arrest
growth arrest and cell death in the breast tumor cell 223-235

HER-2/neu
immunity to HER-2/neu in advanced cancer 245-252
herpes simplex virus thymadine kinase
inducible expression of HSV-tK in breast cancer cells 109-115
hormonal treatment
formestane in elderly breast cancer patients 217-222

immunity
immunity to HER-2/neu in advanced cancer 245-252
inducible promotor
inducible expression of HSV-tK in breast cancer cells 109-115
intraductal components
age and intraductal components in breast cancer 177-184
invasive ductal breast carcinoma
age and intraductal components in breast cancer 177-184
ionizing radiation
growth arrest and cell death in the breast tumor cell 223-235

locally advanced breast cancer
paclitaxel and cisplatin for locally advanced breast cancer 237-244

mammary gland
E6-AP and mouse mammary tumorigenesis 185-195
mammary tumorigenesis
E6-AP and mouse mammary tumorigenesis 185-195
MAP kinase deprivation
MAPK in breast cancer re-growth 167-175

metastatic breast cancer
five-day infusion fluorouracil plus vinorelbine in women 135-139
MIB1
age and intraductal components in breast cancer 177-184
mitogen-activated protein kinase
ras activation in human breast cancer 51-62
mitotic activity
flow cytometry in primary breast carcinomas 117-126

neoadjuvant
paclitaxel and cisplatin for locally advanced breast cancer 237-244
nodal metastases
modal metastases in breast cancer patients with clinically negative lymph nodes 63-69

oncostain M
transcriptional suppression of synuclein γ by oncostatin M 99-107
ovarian cancer
immunity to HER-2/neu in advanced cancer 245-252

PII promoter
a novel silencer element in the aromatase PII promoter 151-159
paclitaxel
cisplatin-epirubicin-paclitaxel in advanced breast cancer 87-97
paclitaxel and cisplatin for locally advanced breast cancer 237-244
phytochemicals
steroid hormonal activity of flavonoids and related compounds 35-49
phytoestrogens
steroid hormonal activity of flavonoids and related compounds 35-49
prevention of breast cancer
review: chemoprevention of breast cancer 1-17
prognostic factors
carcinoma *in situ* of the female breast 197-210
proliferative activity
age and intraductal components in breast cancer 177-184

quality of life
quality of life after adjuvant chemotherapy for breast cancer 141-150

radiotherapy
radiation therapy in the management of brain metastases from breast cancer 211-216
raloxifine
review: chemoprevention of breast cancer 1-17
ras
ras activation in human breast cancer 51-62
retinoids
review: chemoprevention of breast cancer 1-17
risk management
of familial breast cancer risk 19-33

second-line chemotherapy
five-day infusion fluorouracil plus vinorelbine in women 135-139
SERMs
review: chemoprevention of breast cancer 1-17
silencer elements
a novel silencer element in the aromatase PII promoter 151-159
S-phase fraction
flow cytometry in primary breast carcinomas 117-126
steroid hormone receptors
steroid hormonal activity of flavonoids and related compounds 35-49
steroid receptor coactivators
E6-AP and mouse mammary tumorigenesis 185-195
synuclein
transcriptional suppression of synuclein γ by oncostatin M 99-107

tamoxifen
review: chemoprevention of breast cancer 1-17
T-cell
immunity to HER-2/neu in advanced cancer 245-252
transcriptional regulation
MAPK in breast cancer re-growth 167-175

vinorelbine
cyclophosphamide, epirubicin and vinorelbine in advanced breast cancer 127-133

weekly administration
cisplatin-epirubicin-paclitaxel in advanced breast cancer 87-97
whole-body scintigraphy
tetrofsomin in breast cancer diagnosis 253-258